RSV Passive Immunization 69% Effective in Protecting Infants
February 10, 2024 • 6:15 am CST
Eurosurveillance paediatric hospital, Luxembourg, 2022–2023
The journal Eurosurveillance Rapid Communication published a study on January 25, 2024, that concluded Beyfortus™ (Nirsevimab) was about 69% effective at preventing pediatric respiratory syncytial virus (RSV) hospitalizations in infants.
In the context of moderate to high immunization coverage (84%) among neonates, this study provides early real-world evidence of nirsevimab immunization protecting infants from severe RSV disease in Luxembourg.
In 2023, 241 children under five years of age were hospitalized with a laboratory-confirmed RSV infection, compared with 389 cases in 2022, representing decreases of 38% (389 vs. 241) in cases under five years of age and 69% (232 vs. 72) in cases of infants under six months old.
The researchers concluded, ‘Our study shows the impact of nirsevimab in mitigating severe RSV disease among infants during the first RSV season following the national implementation of passive immunization achieving high coverage in Luxembourg. There was a significant increase in the age of hospitalized children, and most severe RSV-related hospitalizations occurred in non-immunized children.’
In previous clinical trials, nirsevimab showed between 74% and 86% efficacy against medically-attended lower respiratory tract infections caused by RSV in healthy infants.
As of February 2024, Beyfortus’s availability in the U.S. has significantly improved.
Our Trust Standards: Medical Advisory Committee
National Public Health Strategy Released to Prevent and Control Vector-Borne Diseases
Trivalent Flu Shot Formulations Coming Next Season
RSV, COVID-19, Flu Hospitalizations Declining in February 2024
Are Yellow Fever Vaccine Boosters Needed
School Vaccinations Increased When Nonmedical Exemptions Were Eliminated
Bladder Cancer Vaccine Therapy Offers Favorable Risk-Benefit Ratio
HIV Vaccine Research Rekindles in 2024
Congenital Syphilis Cases Increased 30% Without a Preventive Vaccine
64% More Measles Cases Last Year
Pregnant Women Prefer RSV Passive Immunization Protection for Infants
Texas Publishes ‘Big Three’ Respiratory Virus Trends and Insights
Houston’s Flu and RSV Season Fizzles Out
Immunize Infants with Beyfortus As Quickly As Possible
Infants Protected From RSV Hospitalizations With Passive Immunization
RSV and Flu Vaccine Coadministration Found Safe
U.S. Government Wants Additional RSV Passive Immunization Supply
3.4% of Expecting Mothers Infected With RSV
RSV Vaccination May Protect Seniors from Hospitalization
4th Vaccine Approved for Pregnant Women
Expecting Mothers Have RSV Prevention Options
RSV Vaccine Now Ava
